BDCM yields 18248.18% · ABBV yields 3.12%● Live data
📍 BDCM pulled ahead of the other in Year 1
Combined, BDCM + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BDCM + ABBV for your $10,000?
LocatI Global Holdings, Inc. develops and licenses global positioning systems (GPS) for tracking, monitoring, surveillance, and recovering automobiles, tractor-trailers, individuals, pets, cargo, medical equipment, ATMs, and electronic equipment. It offers automobile anti-theft tracking devices for tracking location and speed, setting geographic fencing, access via cell or computer, remote locking and unlocking, pinpoint road mapping, and the instant notification of vehicles; and asset protection/loss devices that provide mechanism for businesses to real time access to physical inventory. The company also provides recreation GPS tracking devices that are designed for motorcycles and all-terrain vehicles in the United States, Canada, and Mexico; boat/vessel tracking/monitoring devices to monitor boats and locations; pet tracking and recovery devices for monitoring pets; and personal tracking devices for monitoring people in real time. In addition, it offers electronic equipment protection and recovery devices for cell phones, notebooks, laptops, and desktop computers. The company's products are sold through motorcycle and all-terrain vehicle distributors, as well as automotive retailers; marine stores and boat manufacturers; and veterinarians and large box and pet supply stores. LocatI Global Holdings, Inc. was incorporated in 2011 and is based in Henderson, Nevada.
Full BDCM Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.